Chiasma names new CEO
This article was originally published in Scrip
Executive Summary
Chiasma, a US privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, has appointed Mark Leuchtenberger president and CEO. Mr Leuchtenberger brings 25 years of industry experience to Chiasma, including CEO positions with Acusphere, Rib-X Pharmaceuticals, Targanta Therapeutics and Therion Biologics. From 1996 to 2002, he held multiple senior positions with Biogen, where he managed North American and international commercial operations. He currently serves as advisory board chair of the Massachusetts Emerging Technology Fund, MassDevelopment, and as a trustee and member of the Medical Education Committee, Beth Israel Deaconess Medical Center. And is also a board member of the Massachusetts Biotechnology Council.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.